Chimerism -: Stable mixed chimerism after T cell-depleted allogeneic hematopoietic stem cell transplantation using conditioning with low-dose total body irradiation and fludarabine

被引:10
作者
Görner, M [1 ]
Kordelas, L [1 ]
Thalheimer, M [1 ]
Luft, T [1 ]
Pfeiffer, S [1 ]
Ustaoglu, F [1 ]
Punzel, M [1 ]
Weber-Nordt, R [1 ]
Moos, M [1 ]
Goldschmidt, H [1 ]
Ho, AD [1 ]
机构
[1] Heidelberg Univ, Dept Haematol Oncol & Rheumatol, D-69115 Heidelberg, Germany
关键词
GVHD; T cell depletion; reduced intensity conditioning; non-myeloablative transplantation;
D O I
10.1038/sj.bmt.1703427
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Although reduced intensity conditioning (RIC) before allografting is associated with low treatment-related morbidity and mortality, graft-versus-host disease (GVHD) remains a significant complication of hematopoietic stem cell transplantation (HSCT). T cell depletion (TCD) has been successfully used in conventional allotransplantation to reduce the incidence of GVHD, but was associated with an increased rate of engraftment failure. In a small cohort of six patients at high risk of developing GVHD we have determined whether sustained engraftment could be achieved using reduced intensity conditioning and T cell depletion in combination. All patients engrafted and 5/6 developed high levels (ie greater than or equal to95%) of donor chimerism, even though mismatched related or matched unrelated donors were used. Only one patient developed acute GVHD, as he received donor lymphocyte infusions (DLI) for relapse. In summary, TCD might be a useful prophylactic tool in RIC allogeneic HSCT. Although TCD after RIC might be associated with high relapse rate, as 5/6 patients are not in remission, this combined strategy might be appropriate for patients with less aggressive malignant or non-malignant diseases in which high transplant-related morbidity and mortality is not acceptable.
引用
收藏
页码:621 / 624
页数:4
相关论文
共 19 条
[1]   TRANSPLANTATION OF ALLOGENEIC PERIPHERAL-BLOOD STEM-CELLS MOBILIZED BY RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR [J].
BENSINGER, WI ;
WEAVER, CH ;
APPELBAUM, FR ;
ROWLEY, S ;
DEMIRER, T ;
SANDERS, J ;
STORB, R ;
BUCKNER, CD .
BLOOD, 1995, 85 (06) :1655-1658
[2]   Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation [J].
Childs, R ;
Chernoff, A ;
Contentin, N ;
Bahceci, E ;
Schrump, D ;
Leitman, S ;
Read, EJ ;
Tisdale, J ;
Dunbar, C ;
Linehan, WM ;
Young, NS ;
Barrett, AJ ;
Clave, E ;
Epperson, D ;
Mayo, V .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (11) :750-758
[3]  
Craddock C, 2000, BRIT J HAEMATOL, V111, P797
[4]  
Flowers CR, 2000, BLOOD, V96, p521A
[5]   Mixed chimerism and tolerance without whole body irradiation in a large animal model [J].
Fuchimoto, Y ;
Huang, CA ;
Yamada, K ;
Shimizu, A ;
Kitamura, H ;
Colvin, RB ;
Ferrara, V ;
Murphy, MC ;
Sykes, M ;
White-Scharf, M ;
Neville, DM ;
Sachs, DH .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (12) :1779-1789
[6]   ALLOGENEIC BONE-MARROW TRANSPLANTATION IN MULTIPLE-MYELOMA [J].
GAHRTON, G ;
TURA, S ;
LJUNGMAN, P ;
BELANGER, C ;
BRANDT, L ;
CAVO, M ;
FACON, T ;
GRANENA, A ;
GORE, M ;
GRATWOHL, A ;
LOWENBERG, B ;
NIKOSKELAINEN, J ;
REIFFERS, JJ ;
SAMSON, D ;
VERDONCK, L ;
VOLIN, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (18) :1267-1273
[7]  
Giralt S, 1999, Cancer Treat Res, V101, P97
[8]   The use of CD34+-selected PBPC after high-dose chemotherapy in breast cancer patients is associated with prolonged recovery time and increased infectious complications [J].
Goerner, M ;
Wandt, H ;
Schäfer-Eckart, K ;
Birkmann, J ;
Denzel, T ;
Gallmeier, WM .
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 1999, 8 (04) :387-391
[9]   Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta [J].
Horwitz, EM ;
Prockop, DJ ;
Gordon, PL ;
Koo, WWK ;
Fitzpatrick, LA ;
Neel, MD ;
McCarville, ME ;
Orchard, PJ ;
Pyeritz, RE ;
Brenner, MK .
BLOOD, 2001, 97 (05) :1227-1231
[10]   Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. [J].
Horwitz, ME ;
Barrett, AJ ;
Brown, MR ;
Carter, CS ;
Childs, R ;
Gallin, JI ;
Gress, RE ;
Holland, SM ;
Linton, GF ;
Miller, JA ;
Leitman, SF ;
Read, EJ ;
Schermerhorn, J ;
Malech, HL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (12) :881-888